These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16222321)

  • 1. A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.
    O'Donnell A; Padhani A; Hayes C; Kakkar AJ; Leach M; Trigo JM; Scurr M; Raynaud F; Phillips S; Aherne W; Hardcastle A; Workman P; Hannah A; Judson I
    Br J Cancer; 2005 Oct; 93(8):876-83. PubMed ID: 16222321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
    Stopeck A; Sheldon M; Vahedian M; Cropp G; Gosalia R; Hannah A
    Clin Cancer Res; 2002 Sep; 8(9):2798-805. PubMed ID: 12231519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
    Heymach JV; Desai J; Manola J; Davis DW; McConkey DJ; Harmon D; Ryan DP; Goss G; Quigley T; Van den Abbeele AD; Silverman SG; Connors S; Folkman J; Fletcher CD; Demetri GD
    Clin Cancer Res; 2004 Sep; 10(17):5732-40. PubMed ID: 15355900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.
    Cooney MM; Tserng KY; Makar V; McPeak RJ; Ingalls ST; Dowlati A; Overmoyer B; McCrae K; Ksenich P; Lavertu P; Ivy P; Hoppel CL; Remick S
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):295-300. PubMed ID: 15538570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
    Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.
    Martin LK; Bekaii-Saab T; Serna D; Monk P; Clinton SK; Grever MR; Kraut EH
    Onkologie; 2013; 36(11):657-60. PubMed ID: 24192770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.
    Hoff PM; Wolff RA; Bogaard K; Waldrum S; Abbruzzese JL
    Jpn J Clin Oncol; 2006 Feb; 36(2):100-3. PubMed ID: 16449240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416.
    Dowlati A; Robertson K; Radivoyevitch T; Waas J; Ziats NP; Hartman P; Abdul-Karim FW; Wasman JK; Jesberger J; Lewin J; McCrae K; Ivy P; Remick SC
    Clin Cancer Res; 2005 Nov; 11(21):7938-44. PubMed ID: 16278419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
    Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
    Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
    Giles FJ; Cooper MA; Silverman L; Karp JE; Lancet JE; Zangari M; Shami PJ; Khan KD; Hannah AL; Cherrington JM; Thomas DA; Garcia-Manero G; Albitar M; Kantarjian HM; Stopeck AT
    Cancer; 2003 Apr; 97(8):1920-8. PubMed ID: 12673719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
    Peterson AC; Swiger S; Stadler WM; Medved M; Karczmar G; Gajewski TF
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4048-54. PubMed ID: 15217937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers.
    Fury MG; Zahalsky A; Wong R; Venkatraman E; Lis E; Hann L; Aliff T; Gerald W; Fleisher M; Pfister DG
    Invest New Drugs; 2007 Apr; 25(2):165-72. PubMed ID: 16983506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance.
    Salzberg M; Pless M; Rochlitz C; Ambrus K; Scigalla P; Herrmann R
    Invest New Drugs; 2006 Jul; 24(4):299-304. PubMed ID: 16237511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.
    Mross K; Stefanic M; Gmehling D; Frost A; Baas F; Unger C; Strecker R; Henning J; Gaschler-Markefski B; Stopfer P; de Rossi L; Kaiser R
    Clin Cancer Res; 2010 Jan; 16(1):311-9. PubMed ID: 20028771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
    Kuenen BC; Tabernero J; Baselga J; Cavalli F; Pfanner E; Conte PF; Seeber S; Madhusudan S; Deplanque G; Huisman H; Scigalla P; Hoekman K; Harris AL
    Clin Cancer Res; 2003 May; 9(5):1648-55. PubMed ID: 12738717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous determination of Z-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone (SU5416) and its interconvertible geometric isomer (SU5886) in rat plasma by LC/MS/MS.
    Zhao Y; Sukbuntherng J
    J Pharm Biomed Anal; 2005 Jul; 38(3):479-86. PubMed ID: 15925249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin.
    Overmoyer B; Fu P; Hoppel C; Radivoyevitch T; Shenk R; Persons M; Silverman P; Robertson K; Ziats NP; Wasman JK; Abdul-Karim FW; Jesberger JA; Duerk J; Hartman P; Hanks S; Lewin J; Dowlati A; McCrae K; Ivy P; Remick SC
    Clin Cancer Res; 2007 Oct; 13(19):5862-8. PubMed ID: 17908980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.
    Kieran MW; Supko JG; Wallace D; Fruscio R; Poussaint TY; Phillips P; Pollack I; Packer R; Boyett JM; Blaney S; Banerjee A; Geyer R; Friedman H; Goldman S; Kun LE; Macdonald T;
    Pediatr Blood Cancer; 2009 Feb; 52(2):169-76. PubMed ID: 19065567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
    Stadler WM; Cao D; Vogelzang NJ; Ryan CW; Hoving K; Wright R; Karrison T; Vokes EE
    Clin Cancer Res; 2004 May; 10(10):3365-70. PubMed ID: 15161690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.